Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 10/20 | 0.39 |
| ▸ | DRD2 | P14416 | 3/20 | 0.39 |
| ▸ | DRD3 | P35462 | 3/20 | 0.39 |
| ▸ | DAO | P14920 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2084761 | 0.88 | ADORA3 (0.42) | ADORA3ADORA2AADORA2BADORA1LMNA | |
| SCHEMBL25817348 | 0.80 | ADORA3 (0.46) | ADORA3ADORA2AADORA2BADORA1LMNA | |
| SCHEMBL4639176 | 0.77 | DAO (0.46) | LMNADAOCYP1A2MEN1KMT2A | |
| SCHEMBL13015485 | 0.73 | DAO (0.48) | ADORA3ADORA2AADORA2BADORA1LMNA | |
| SCHEMBL2085663 | 0.72 | RXFP1 (0.34) | ADORA3ADORA2AADORA2BADORA1LMNA | |
| SCHEMBL13015480 | 0.71 | DAO (0.66) | ADORA3ADORA2AADORA2BADORA1LMNA | |
| SCHEMBL3288733 | 0.71 | HTR1A (0.44) | ADORA3ADORA2AADORA2BADORA1LMNA | |
| SCHEMBL3285641 | 0.71 | HTR1A (0.44) | ADORA3ADORA2AADORA2BADORA1LMNA | |
| SCHEMBL8471506 | 0.70 | CYP1A2 (0.43) | LMNAHTR1ADRD2DRD3DAO | |
| SCHEMBL25122976 | 0.70 | MEN1 (0.51) | ADORA3ADORA2AADORA2BADORA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163935-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090312383-A1 | Fused Heterocyclic Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312383-A1 | Fused Heterocyclic Compounds | NPY4R, CRHR1, CNR1 | ADORA3 295/4885ADORA2A 658/4885ADORA2B 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.